Stop TB Partnership

Global Drug Facility reaches a 58% price reduction for Rifabutin by adding a new supplier to its product catalogue


06 June 2014 - Geneva - The Stop TB Partnership Global Drug Facility (GDF) has achieved a near 60% reduction in the price of Rifabutin, by including a new supplier into its product catalogue.

Rifabutin is from the rifamycin class and is used in treatment for drug sensitive TB. It was recently included in the HIV treatment guidelines in which it is recommended that all people with HIV and active TB start immediate treatment including a rifamycin, preferably rifabutin.

The price reduction follows a competitive tendering process among eligible anti-TB drug manufacturers and ongoing efforts by GDF to broaden the supplier base for quality-assured anti-TB drugs.

"GDF is committed to improve access to quality assured treatments for people in need and constantly looking for strategies to reduce treatment costs," Dr Joel Keravec, Manager of GDF at Stop TB Partnership said.

GDF customers can place orders for a US-FDA approved quality Rifabutin manufacturer as of today at a price of 0.42 USD per tablet. Currently GDF has 2 quality assured suppliers for this product available to our customers world-wide.

For more information consult GDF product catalogue.